Monopar Therapeutics (MNPR) Return on Capital Employed (2018 - 2026)
Monopar Therapeutics (MNPR) posted Return on Capital Employed of 12.57% for Q3 2025, up 32.3% sequentially from 18.57% in Q2 2025.
Monopar Therapeutics (MNPR) Return on Capital Employed (2018 - 2026) Analysis & Trends
Monopar Therapeutics has reported Return on Capital Employed for 7 years, with the latest figure at 12.57% in Q3 2025.
- Quarterly Return on Capital Employed changed N/A year-over-year to 12.57% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 12.57% (changed N/A YoY) and the FY2025 annual result came in at 8.72%, up 39.0% from the prior year.
- Return on Capital Employed rose to 12.57% in Q3 2025 per MNPR's latest filing, from 18.57% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 12.57% in Q3 2025 and troughed at 131.32% in Q3 2023.
- A 4-year average of 69.73% and a median of 68.1% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2021 and 2023: Return on Capital Employed tumbled 328 bps in 2021, then sank 5680 bps in 2023.
- Over 4 years, Return on Capital Employed stood at 45.78% in 2021, then tumbled by 115 bps to 98.41% in 2022, then slumped by 33 bps to 131.32% in 2023, then jumped by 90 bps to 12.57% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 12.57%, 18.57%, and 131.32% for Q3 2025, Q2 2025, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | -12.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.85% |
| Sep 30, 2025 | -12.57% |
| Jun 30, 2025 | -18.57% |
| Sep 30, 2023 | -131.32% |
| Jun 30, 2023 | -118.48% |
| Mar 31, 2023 | -109.99% |
| Dec 31, 2022 | -98.41% |
| Sep 30, 2022 | -75.38% |
| Jun 30, 2022 | -68.10% |
| Mar 31, 2022 | -53.18% |
| Dec 31, 2021 | -45.78% |
| Mar 31, 2021 | -35.31% |
| Dec 31, 2020 | -39.84% |
| Sep 30, 2020 | -36.81% |
| Jun 30, 2020 | -37.43% |
| Mar 31, 2020 | -32.03% |
| Dec 31, 2019 | -50.83% |
| Sep 30, 2019 | -82.68% |
| Jun 30, 2019 | -71.43% |
| Mar 31, 2019 | -58.64% |